AR and posterior cortical atrophy: Traditionally the use of molecularly targeted therapy in PCa focused on the inhibition of oncogenic drivers (e.g., androgen receptor (AR)) and first-generation AR targeted agents (flutamide, bicutamide and nilutamide) dominated the treatment paradigm since the seminal paper by Huggins et al. over fifty years ago [5,6].